Immunotherapy with anti-PD-1 and anti-PD-L1 monoclonal antibodies blocks the PD-1/PD-L1 pathway, making tumor cells visible to the immune system and allowing it to activate immune factors leading to the elimination of cancer cells (Sun et al. 2020; Makuku et al 2021). The gene discussed is CD274; the disease is cancer.